CovidChloroV1, Main, Corpus, bibRecord, 000B14

Rationale for ozone-therapy as an adjuvant therapy in COVID-19: a narrative review.

Identifieur interne : 000B14 ( Main/Corpus ); précédent : 000B13; suivant : 000B15

Rationale for ozone-therapy as an adjuvant therapy in COVID-19: a narrative review.

Auteurs : Giovanni Tommaso Ranaldi ; Emanuele Rocco Villani ; Laura Franza

Source :

Medical gas research [ 2045-9912 ]

RBID : pubmed:33004712

English descriptors

KwdEn :
- Betacoronavirus (isolation & purification), COVID-19 (MeSH), Combined Modality Therapy (MeSH), Coronavirus Infections (physiopathology), Coronavirus Infections (therapy), Coronavirus Infections (virology), Humans (MeSH), Ozone (therapeutic use), Pandemics (MeSH), Pneumonia, Viral (physiopathology), Pneumonia, Viral (therapy), Pneumonia, Viral (virology), SARS-CoV-2 (MeSH), Treatment Outcome (MeSH).
MESH :
- chemical , therapeutic use : Ozone.
- isolation & purification : Betacoronavirus.
- physiopathology : Coronavirus Infections, Pneumonia, Viral.
- therapy : Coronavirus Infections, Pneumonia, Viral.
- virology : Coronavirus Infections, Pneumonia, Viral.
- COVID-19, Combined Modality Therapy, Humans, Pandemics, SARS-CoV-2, Treatment Outcome.

Abstract

Coronavirus disease 2019 (COVID-19) is the respiratory disease caused by the novel severe acute respiratory syndrome-coronavirus-2 and is characterized by clinical manifestations ranging from mild, flu-like symptoms to severe respiratory insufficiency and multi-organ failure. Patients with more severe symptoms may require intensive care treatments and face a high mortality risk. Also, thrombotic complications such as pulmonary embolisms and disseminated intravascular coagulation are frequent in these patients. Indeed, COVID-19 is characterized by an abnormal inflammatory response resembling a cytokine storm, which is associated to endothelial dysfunction and microvascular complications. To date, no specific treatments are available for COVID-19 and its life-threatening complication. Immunomodulatory drugs, such as hydroxychloroquine and interleukin-6 inhibitors, as well as antithrombotic drugs such as heparin and low molecular weight heparin, are currently being administered with some benefit. Ozone therapy consists in the administration of a mixture of ozone and oxygen, called medical ozone, which has been used for over a century as an unconventional medicine practice for several diseases. Medical ozone rationale in COVID-19 is the possibility of contrasting endothelial dysfunction, modulating the immune response and acting as a virustatic agent. Thus, medical ozone could help to decrease lung inflammation, slow down viral growth, regulate lung circulation and oxygenation and prevent microvascular thrombosis. Ozone-therapy could be considered a feasible, cost-effective and easy to administer adjuvant therapy while waiting for the synthesis of a therapy or the development of the vaccine.

DOI: 10.4103/2045-9912.289462
PubMed: 33004712
PubMed Central: PMC8086623

Links to Exploration step

pubmed:33004712

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Rationale for ozone-therapy as an adjuvant therapy in COVID-19: a narrative review.</title>
<author><name sortKey="Ranaldi, Giovanni Tommaso" sort="Ranaldi, Giovanni Tommaso" uniqKey="Ranaldi G" first="Giovanni Tommaso" last="Ranaldi">Giovanni Tommaso Ranaldi</name>
<affiliation><nlm:affiliation>Unità Operativa Semplice Dipartimentale Farmacologia Clinica e Sperimentazione Clinica, Azienda Sanitaria, Potenza, Italy.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Villani, Emanuele Rocco" sort="Villani, Emanuele Rocco" uniqKey="Villani E" first="Emanuele Rocco" last="Villani">Emanuele Rocco Villani</name>
<affiliation><nlm:affiliation>Department of Geriatrics, Università Cattolica del Sacro Cuore, Rome, Italy.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Franza, Laura" sort="Franza, Laura" uniqKey="Franza L" first="Laura" last="Franza">Laura Franza</name>
<affiliation><nlm:affiliation>Department of Emergency Medicine, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020 Jul-Sep</date>
<idno type="RBID">pubmed:33004712</idno>
<idno type="pmid">33004712</idno>
<idno type="doi">10.4103/2045-9912.289462</idno>
<idno type="pmc">PMC8086623</idno>
<idno type="wicri:Area/Main/Corpus">000B14</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000B14</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Rationale for ozone-therapy as an adjuvant therapy in COVID-19: a narrative review.</title>
<author><name sortKey="Ranaldi, Giovanni Tommaso" sort="Ranaldi, Giovanni Tommaso" uniqKey="Ranaldi G" first="Giovanni Tommaso" last="Ranaldi">Giovanni Tommaso Ranaldi</name>
<affiliation><nlm:affiliation>Unità Operativa Semplice Dipartimentale Farmacologia Clinica e Sperimentazione Clinica, Azienda Sanitaria, Potenza, Italy.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Villani, Emanuele Rocco" sort="Villani, Emanuele Rocco" uniqKey="Villani E" first="Emanuele Rocco" last="Villani">Emanuele Rocco Villani</name>
<affiliation><nlm:affiliation>Department of Geriatrics, Università Cattolica del Sacro Cuore, Rome, Italy.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Franza, Laura" sort="Franza, Laura" uniqKey="Franza L" first="Laura" last="Franza">Laura Franza</name>
<affiliation><nlm:affiliation>Department of Emergency Medicine, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Medical gas research</title>
<idno type="eISSN">2045-9912</idno>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Betacoronavirus (isolation & purification)</term>
<term>COVID-19 (MeSH)</term>
<term>Combined Modality Therapy (MeSH)</term>
<term>Coronavirus Infections (physiopathology)</term>
<term>Coronavirus Infections (therapy)</term>
<term>Coronavirus Infections (virology)</term>
<term>Humans (MeSH)</term>
<term>Ozone (therapeutic use)</term>
<term>Pandemics (MeSH)</term>
<term>Pneumonia, Viral (physiopathology)</term>
<term>Pneumonia, Viral (therapy)</term>
<term>Pneumonia, Viral (virology)</term>
<term>SARS-CoV-2 (MeSH)</term>
<term>Treatment Outcome (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Ozone</term>
</keywords>
<keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>COVID-19</term>
<term>Combined Modality Therapy</term>
<term>Humans</term>
<term>Pandemics</term>
<term>SARS-CoV-2</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Coronavirus disease 2019 (COVID-19) is the respiratory disease caused by the novel severe acute respiratory syndrome-coronavirus-2 and is characterized by clinical manifestations ranging from mild, flu-like symptoms to severe respiratory insufficiency and multi-organ failure. Patients with more severe symptoms may require intensive care treatments and face a high mortality risk. Also, thrombotic complications such as pulmonary embolisms and disseminated intravascular coagulation are frequent in these patients. Indeed, COVID-19 is characterized by an abnormal inflammatory response resembling a cytokine storm, which is associated to endothelial dysfunction and microvascular complications. To date, no specific treatments are available for COVID-19 and its life-threatening complication. Immunomodulatory drugs, such as hydroxychloroquine and interleukin-6 inhibitors, as well as antithrombotic drugs such as heparin and low molecular weight heparin, are currently being administered with some benefit. Ozone therapy consists in the administration of a mixture of ozone and oxygen, called medical ozone, which has been used for over a century as an unconventional medicine practice for several diseases. Medical ozone rationale in COVID-19 is the possibility of contrasting endothelial dysfunction, modulating the immune response and acting as a virustatic agent. Thus, medical ozone could help to decrease lung inflammation, slow down viral growth, regulate lung circulation and oxygenation and prevent microvascular thrombosis. Ozone-therapy could be considered a feasible, cost-effective and easy to administer adjuvant therapy while waiting for the synthesis of a therapy or the development of the vaccine.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33004712</PMID>
<DateCompleted><Year>2020</Year>
<Month>10</Month>
<Day>13</Day>
</DateCompleted>
<DateRevised><Year>2021</Year>
<Month>05</Month>
<Day>07</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2045-9912</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>10</Volume>
<Issue>3</Issue>
<PubDate><MedlineDate>2020 Jul-Sep</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Medical gas research</Title>
<ISOAbbreviation>Med Gas Res</ISOAbbreviation>
</Journal>
<ArticleTitle>Rationale for ozone-therapy as an adjuvant therapy in COVID-19: a narrative review.</ArticleTitle>
<Pagination><MedlinePgn>134-138</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4103/2045-9912.289462</ELocationID>
<Abstract><AbstractText>Coronavirus disease 2019 (COVID-19) is the respiratory disease caused by the novel severe acute respiratory syndrome-coronavirus-2 and is characterized by clinical manifestations ranging from mild, flu-like symptoms to severe respiratory insufficiency and multi-organ failure. Patients with more severe symptoms may require intensive care treatments and face a high mortality risk. Also, thrombotic complications such as pulmonary embolisms and disseminated intravascular coagulation are frequent in these patients. Indeed, COVID-19 is characterized by an abnormal inflammatory response resembling a cytokine storm, which is associated to endothelial dysfunction and microvascular complications. To date, no specific treatments are available for COVID-19 and its life-threatening complication. Immunomodulatory drugs, such as hydroxychloroquine and interleukin-6 inhibitors, as well as antithrombotic drugs such as heparin and low molecular weight heparin, are currently being administered with some benefit. Ozone therapy consists in the administration of a mixture of ozone and oxygen, called medical ozone, which has been used for over a century as an unconventional medicine practice for several diseases. Medical ozone rationale in COVID-19 is the possibility of contrasting endothelial dysfunction, modulating the immune response and acting as a virustatic agent. Thus, medical ozone could help to decrease lung inflammation, slow down viral growth, regulate lung circulation and oxygenation and prevent microvascular thrombosis. Ozone-therapy could be considered a feasible, cost-effective and easy to administer adjuvant therapy while waiting for the synthesis of a therapy or the development of the vaccine.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ranaldi</LastName>
<ForeName>Giovanni Tommaso</ForeName>
<Initials>GT</Initials>
<AffiliationInfo><Affiliation>Unità Operativa Semplice Dipartimentale Farmacologia Clinica e Sperimentazione Clinica, Azienda Sanitaria, Potenza, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Villani</LastName>
<ForeName>Emanuele Rocco</ForeName>
<Initials>ER</Initials>
<AffiliationInfo><Affiliation>Department of Geriatrics, Università Cattolica del Sacro Cuore, Rome, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Franza</LastName>
<ForeName>Laura</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Department of Emergency Medicine, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>Australia</Country>
<MedlineTA>Med Gas Res</MedlineTA>
<NlmUniqueID>101564536</NlmUniqueID>
<ISSNLinking>2045-9912</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>66H7ZZK23N</RegistryNumber>
<NameOfSubstance UI="D010126">Ozone</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName>
<QualifierName UI="Q000302" MajorTopicYN="Y">isolation & purification</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010126" MajorTopicYN="N">Ozone</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">COVID-19</Keyword>
<Keyword MajorTopicYN="Y">SARS-COV-2</Keyword>
<Keyword MajorTopicYN="Y">cytokine storm</Keyword>
<Keyword MajorTopicYN="Y">endothelial dysfunction</Keyword>
<Keyword MajorTopicYN="Y">immunomodulation</Keyword>
<Keyword MajorTopicYN="Y">medical ozone</Keyword>
<Keyword MajorTopicYN="Y">ozone</Keyword>
<Keyword MajorTopicYN="Y">ozone therapy</Keyword>
<Keyword MajorTopicYN="Y">virustatic</Keyword>
</KeywordList>
<CoiStatement>None</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>10</Month>
<Day>2</Day>
<Hour>5</Hour>
<Minute>36</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>10</Month>
<Day>3</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>10</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">33004712</ArticleId>
<ArticleId IdType="pii">MedGasRes_2020_10_3_134_289462</ArticleId>
<ArticleId IdType="doi">10.4103/2045-9912.289462</ArticleId>
<ArticleId IdType="pmc">PMC8086623</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Liver Int. 2020 Sep;40(9):2095-2103</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32239796</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Annu Rev Virol. 2016 Sep 29;3(1):237-261</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27578435</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Metab. 2018 Aug;14:71-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29914852</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Intern Med. 2020 Jun 2;172(11):754-755</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32232419</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Thromb Haemost. 2020 Jul;18(7):1752-1755</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32267998</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Anaesthesiol Intensive Ther. 2016;48(4):261-265</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27660252</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Brain Behav Immun. 2020 Jul;87:18-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32240762</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Anaesth Crit Care Pain Med. 2020 Jun;39(3):389-390</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32305591</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Environ Health. 1979 Sep-Oct;34(5):346-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">496433</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Pharmacol. 2014 Nov 5;742:158-62</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25218903</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Regul Homeost Agents. 2019 Sep-Oct;33(5):1321-1326</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31663301</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Med Sci. 2011 Jan 03;8(1):48-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21234269</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Pathog. 2019 Jun 6;15(6):e1007795</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31170267</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Mar 26;382(13):1199-1207</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31995857</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Diabetes Obes Metab. 2015 May;17(5):435-44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25469642</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Respir Med. 2020 Apr;8(4):420-422</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32085846</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Med Gas Res. 2020 Apr-Jun;10(2):61-62</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32541128</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Gastroenterol. 2010 May 05;10:42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20444253</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Leukoc Biol. 2005 May;77(5):598-625</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15689384</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 Apr 28;323(16):1574-1581</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32250385</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mediators Inflamm. 1998;7(5):313-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9883965</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Blood Cells Mol Dis. 2009 May-Jun;42(3):267-78</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19233695</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bioorg Med Chem Lett. 1999 Nov 15;9(22):3255-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10576698</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Thromb Haemost. 2020 May;18(5):1020-1022</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32239799</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Acta Reumatol Port. 2018 Jul-Sep;43(3):210-216</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30414369</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Thromb Haemost. 2020 Apr;18(4):844-847</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32073213</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biomolecules. 2018 Dec 17;8(4):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30563025</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pol Merkur Lekarski. 2001 Aug;11(62):180-1</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11757225</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Emerg Med. 2007 Jan;49(1):88-98, 98.e1-2</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17095120</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2009 Jan 27;106(4):1285-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19164583</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Invest. 2018 May 1;128(5):2064-2075</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29664014</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Toxicol Appl Pharmacol. 1997 Nov;147(1):71-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9356309</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cochrane Database Syst Rev. 2015 Oct 27;(10):CD008474</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26505864</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Anaesthesiol Intensive Ther. 2020;52(1):34-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32191830</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Semin Immunopathol. 2017 Jul;39(5):529-539</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28466096</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Dent Res. 2007 May;86(5):451-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17452567</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Biol Macromol. 2006 Nov 15;39(4-5):317-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16712921</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2020 Apr;20(4):400-402</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32113509</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Toxicol Appl Pharmacol. 2016 Aug 15;305:40-45</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27286659</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mediators Inflamm. 2005 Feb 24;2005(1):16-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15770062</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Microbiol. 2016 Jul 30;16(1):173</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27475908</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Semin Thromb Hemost. 2015 Sep;41(6):659-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26305236</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2019 Sep 25;14(9):e0222601</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31553765</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Int Med Res. 1994 May-Jun;22(3):131-44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8088420</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Transl Res. 2020 Jun;220:1-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32299776</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Med Gas Res. 2017 Oct 17;7(3):212-219</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29152215</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int Angiol. 1997 Dec;16(4):250-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9543222</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>AJR Am J Roentgenol. 2020 Jul;215(1):87-93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32174129</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Free Radic Biol Med. 1991;11(1):81-128</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1937131</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Korean J Intern Med. 2015 Jan;30(1):1-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25589827</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Virol. 2020 Apr;92(4):424-432</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31981224</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arterioscler Thromb Vasc Biol. 2009 Oct;29(10):1537-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19542024</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Water Res. 2019 Sep 1;160:339-349</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31158616</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Toxicol Appl Pharmacol. 2001 May 15;173(1):18-26</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11350211</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA Neurol. 2020 Jun 1;77(6):683-690</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32275288</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Med Res Rev. 2009 Jul;29(4):646-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19260079</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B14 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000B14 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:33004712
   |texte=   Rationale for ozone-therapy as an adjuvant therapy in COVID-19: a narrative review.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i   -Sk "pubmed:33004712" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidChloroV1

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021

	Serveur d'exploration COVID et hydrochloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration COVID et hydrochloroquine

Rationale for ozone-therapy as an adjuvant therapy in COVID-19: a narrative review.

Rationale for ozone-therapy as an adjuvant therapy in COVID-19: a narrative review.

Source :

English descriptors

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki